Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines

Pharmacogenomics Journal

Volumn 17, Issue 2, 2017, Pages 137-145

  Chhibber, A ^a   French, C E ^b   Yee, S W ^a   Gamazon, E R ^c,d   Theusch, E ^e   Qin, X ^f   Webb, A ^g   Papp, A C ^g   Wang, A ^e   Simmons, C Q ^c   Konkashbaev, A ^c   Chaudhry, A S ^h   Mitchel, K ^e   Stryke, D ^a   Ferrin, T E ^a   Weiss, S T ⁱ   Kroetz, D L ^a   Sadee, W ^g,j   Nickerson, D A ^k   Krauss, R M ^e   George, A L ^l   Schuetz, E G ^h   Medina, M W ^e   Cox, N J ^c   Scherer, S E ^f   Giacomini, K M ^a   Brenner, S E ^b,m   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHANNEL NAV1.5; TRANSCRIPTOME;

ADIPOSE TISSUE; ALTERNATIVE RNA SPLICING; ARTICLE; DRUG DISPOSITION; GENE EXPRESSION; HEART TISSUE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TISSUE; LIVER TISSUE; LYMPHOBLASTOID CELL LINE; NONSENSE MEDIATED MRNA DECAY; PHARMACOGENOMICS; RNA SEQUENCE; TRANSCRIPTOMICS; BIOLOGY; CARDIAC MUSCLE; CELL LINE; GENETIC DATABASE; GENOTYPE; HIGH THROUGHPUT SEQUENCING; KIDNEY; LIVER; METABOLISM; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; SEQUENCE ANALYSIS;

ADIPOSE TISSUE; ALTERNATIVE SPLICING; CELL LINE; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KIDNEY; LIVER; MYOCARDIUM; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME;

EID: 84957831292     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.93     Document Type: Article

References (75)

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
2. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
3. Mohamed S, Syed BA. Commercial prospects for genomic sequencing technologies. Nat Rev Drug Discov 2013; 12: 341-342.
4. Smith RP, Lam ET, Markova S, Yee SW, Ahituv N. Pharmacogene regulatory elements: from discovery to applications. Genome Med 2012; 4: 45.
5. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet 2014; 30: 418-426.
6. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012; 7: 562-578.
7. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010; 11: R106.
8. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNAseq data. Genome Res 2012; 22: 2008-2017.
9. Katz Y, Wang ET, Airoldi EM, Burge CB. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 2010; 7: 1009-1015.
10. Brooks AN, Yang L, Duff MO, Hansen KD, Park JW, Dudoit S et al. Conservation of an RNA regulatory map between Drosophila and mammals. Genome Res 2011; 21: 193-202.
11. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med 2013; 5: 189sr184.
12. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580-585.
13. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 2012; 22: 1760-1774.
14. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
15. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDPglucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 2002; 62: 446-450.
16. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 2014; 23: 268-278.
17. Kim J, Zhao K, Jiang P, Lu ZX, Wang J, Murray JC et al. Transcriptome landscape of the human placenta. BMC Genomics 2012; 13: 115.
18. Farkas MH, Grant GR, White JA, Sousa ME, Consugar MB, Pierce EA. Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. BMC Genomics 2013; 14: 486.
19. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621-628.
20. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR et al. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol 2013; 9: 459-472.
21. Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab 2012; 13: 1327-1344.
22. Masereeuw R, Russel FG. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther 2010; 126: 200-216.
23. Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability-considerations for drug development. Expert Opin Drug Metab Toxicol 2012; 8: 723-743.
24. Huang RS, Duan S, Kistner EO, Zhang W, Bleibel WK, Cox NJ et al. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics 2008; 18: 545-549.
25. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI et al. A statin-dependent QTL for GATM expression is associated with statininduced myopathy. Nature 2013; 502: 377-380.
26. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012; 13: 55-70.
27. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414-417.
28. Montreal Heart Institute Pharmacogenomics Center (2013). PharmaADME.
29. U.S. Food and Drug Admnistration (2013). Table of Pharmacogenomic Biomarkers in Drug Labels.
30. Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 2013; 15: 648-659.
31. Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, Milani L. Insolution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. Nucleic Acids Res 2013; 41: e72.
32. Gamazon ER, Skol AD, Perera MA. The limits of genome-wide methods for pharmacogenomic testing. Pharmacogenet Genomics 2012; 22: 261-272.
33. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 2010; 11: 89-103.
34. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS, Diekhans M et al. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res 2014; 42: D764-D770.
35. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-1111.
36. Consortium GT, Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015; 348: 648-660.
37. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29.
38. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annu Rev Pharmacol Toxicol 2013; 53: 503-529.
39. Rask-Andersen M, Masuram S, Schioth HB. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol 2014; 54: 9-26.
40. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341: 1447-1457.
41. George AL Jr. Recent genetic discoveries implicating ion channels in human cardiovascular diseases. Curr Opin Pharmacol 2014; 15: 47-52.
42. Oshiro C, Thorn CF, Roden DM, Klein TE, Altman RB. KCNH2 pharmacogenomics summary. Pharmacogenet Genomics 2010; 20: 775-777.
43. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413-1415.
44. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008; 321: 956-960.
45. Li M, Jia C, Kazmierkiewicz KL, Bowman AS, Tian L, Liu Y et al. Comprehensive analysis of gene expression in human retina and supporting tissues. Hum Mol Genet 2014; 23: 4001-4014.
46. Webb A, Papp AC, Sanford JC, Huang K, Parvin JD, Sadee W. Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. Pharmacogenet Genomics 2013; 23: 269-278.
47. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom 2014; 13: 397-406.
48. Gremel G, Wanders A, Cedernaes J, Fagerberg L, Hallstrom B, Edlund K et al. The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling. J Gastroenterol 2014; 50: 46-57.
49. Choi YS, Dusting GJ, Stubbs S, Arunothayaraj S, Han XL, Collas P et al. Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med 2010; 14: 878-889.
50. Planat-Benard V, Menard C, Andre M, Puceat M, Perez A, Garcia-Verdugo JM et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 2004; 94: 223-229.
51. Makita N, Horie M, Nakamura T, Ai T, Sasaki K, Yokoi H et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002; 106: 1269-1274.
52. Shuraih M, Ai T, Vatta M, Sohma Y, Merkle EM, Taylor E et al. A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents. J Cardiovasc Electrophysiol 2007; 18: 434-440.
53. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA 2003; 100: 189-192.
54. Cropp CD, Komori T, Shima JE, Urban TJ, Yee SW, More SS et al. Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 2008; 73: 1151-1158.
55. Dahlin A, Geier E, Stocker SL, Cropp CD, Grigorenko E, Bloomer M et al. Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm 2013; 10: 650-663.
56. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 2005; 33: 619-622.
57. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005; 57: 573-578.
58. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
59. U.S. Department of Health and Human Services FaDAF, (CDER) CfDEaR (2012). Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.
60. Wempe MF, Lightner JW, Miller B, Iwen TJ, Rice PJ, Wakui S et al. Potent human uric acid transporter 1 inhibitors: in vitro and in vivo metabolism and pharmacokinetic studies. Drug Design Dev Ther 2012; 6: 323-339.
61. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
62. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-823.
63. Wernicke C, Hellmann J, Finckh U, Rommelspacher H. Chronic ethanol exposure changes dopamine D2 receptor splicing during retinoic acid-induced differentiation of human SH-SY5Y cells. Pharmacol Rep 2010; 62: 649-663.
64. Medina MW, Gao F, Naidoo D, Rudel LL, Temel RE, McDaniel AL et al. Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake. PLoS ONE 2011; 6: e19420.
65. Solier S, Barb J, Zeeberg BR, Varma S, Ryan MC, Kohn KW et al. Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res 2010; 70: 8055-8065.
66. Stormo C, Kringen MK, Lyle R, Olstad OK, Sachse D, Berg JP et al. RNA-Sequencing Analysis of HepG2 Cells Treated with Atorvastatin. PLoS ONE 2014; 9: e105836.
67. Vivarelli S, Lenzken SC, Ruepp MD, Ranzini F, Maffioletti A, Alvarez R et al. Paraquat modulates alternative pre-mRNA splicing by modifying the intracellular distribution of SRPK2. PLoS ONE 2013; 8: e61980.
68. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100: 1896-1901.
69. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008; 6: e107.
70. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012; 52: 21-35.
71. Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med 2013; 5: 5.
72. Barrie ES, Smith RM, Sanford JC, Sadee W. mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol 2012; 81: 620-630.
73. Pal S, Gupta R, Kim H, Wickramasinghe P, Baubet V, Showe LC et al. Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development. Genome Res 2011; 21: 1260-1272.
74. Warnes GR Gplots: Various R Programming Tools for Plotting Data 2015.
75. Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer: NY, USA, 2009.